Smart AI Quantification for Precision Medicine
We innovate pathology with AI-powered biomarker quantification in precision medicine. Our technology enables fast and accurate patient screening for targeted cancer therapy, thus improving patient outcomes worldwide.
What makes AIVIS special?
Practical Solution
MFDS-certified for clinical use—fast, accurate, and seamlessly integrated with an intuitive UI/UX for maximum efficiency
Robustness
Extensive internal and extensive validation across diverse staining protocols and scanners with leading hospitals
Pathologist-Friendly
Developed and managed by our dedicated in-house pathologists, ensuring unmatched accuracy at the cellular level and deep clinical relevance
Patient Privacy & Data Security
Advanced security and anonymization protocols safeguard patient data with the highest standards
Pioneering Precision Medicine through AI
Our Milestones
2024
2023
2022
2021
Obtention of the Medical Device Quality Management System Certificate (ISO 13485:2016)
Obtention of the Korea Good Manufacturing Practices of In-Vitro Diagnostic Device (KGMP)
Launch of "PathoAiD®-Qanti IHC" - A solution for Quantifying Companion Diagnostic Biomarkers ER, PR, HER2, and Ki-67 based on IHC-stained histopathology images
Launch of "PathoAiD®-Thyroid Dx" - A precision Pathology Diagnostic solution for thyroid nodules based on Core Needle Biopsy (CNB)
Launch of "PathoAiD®-Colon Dx" - A precision Pathology Diagnostic solution for colorectal polyps
Our Leadership
Chief Executive Officer
Daehong Lee
Ph.D.
Daehong Lee is a distinguished leader in the field of technology, currently serving as CEO of AIVIS Inc., leading the company's vision and strategy. With a robust background in electrical engineering from Korea University and a Ph.D. in Computer Vision and Image Processing, Dr. Lee brings extensive expertise to his role. His career includes significant experience as a senior researcher at Suprema Inc., where he developed advanced fingerprint and facial recognition solutions. In 2020, he managed the pioneering project of developing the world's first under-display fingerprint recognition solution, successfully integrated into devices like the Galaxy S10, A50, and A70, marking a milestone in the industry.
Chief Technology Officer
Hyeongcheol An
M.S.
Hyeongcheol An is a seasoned expert in cloud architecture and SaaS platform engineering, currently serving as CTO of AIVIS Inc., where he leads the company’s technical strategy and infrastructure innovation. He holds a Master’s degree in Information Security from KAIST, specializing in cryptography, and brings deep knowledge of scalable system design and secure computing. His career includes key roles at LG CNS, where he developed blockchain-based enterprise systems as part of an internal venture, focusing on software architecture and innovation, and at Archidraw, where heㅤ led the architecture of a 3D interior design SaaS solution with a strong emphasis on high-performance cloud platforms. At AIVIS, he is responsible for designing, building, and optimizing a microservices-based system, with a focus on cloud architecture and cost optimization. He continues to enhance engineering efficiency through DevOps practices, CI/CD automation, and comprehensive system observability.
Chief Medical Officer
Gyuyeong Kim
M.D.
Gyuyeong Kim is the CMO of AIVIS, where he designs products to address the practical problems faced by pathologists. Leveraging his medical experience, he ensures that AIVIS's solutions effectively meet users' needs. Dr. Kim was trained as a pathology resident at Samsung Medical Center and has conducted research in digital pathology, focusing on visual feature representation and evaluation metrics. He actively engages with the pathology community by attending and presenting at conferences, staying informed of the latest trends. This engagement allows him to lead our product development direction with cutting-edge insights and knowledge.
